The National Institute for Health Research (NIHR) and IQVIA - the global health technology and human data science company – are today (Monday, 25th November) inaugurating their Northern Prime Site, focusing on the delivery of life-changing clinical research across the North of England. The site is the fourth IQVIA Prime Site in the UK and will employ more than 50 newly recruited high-skilled staff, to enable this ground-breaking relationship. It supports a significant increase in clinical trials and real world evidence studies within the region over the coming years.
IQVIA currently conducts more than 20% of all commercial clinical trials in the NHS and the Northern Prime Site will bring together NHS research-ready hospitals across Greater Manchester and the Yorkshire and Humber region. The Prime Site is differentiated from other research centres in that it will embrace a health data-enabled, technology-rich approach to the design and delivery of hundreds of additional clinical trials and real world evidence studies which have the potential of transforming healthcare outcomes for thousands of NHS patients.
The inauguration took place at the Clinical Research Faculty at Sheffield Teaching Hospital NHS Foundation Trust. Guests included Yorkshire and Humber and Greater Manchester NIHR Clinical Research Network senior leaders, NHS Trust CEOs and University Vice Chancellors from across the North of England.
The Northern Prime event is supported by the release of a new White Paper from IQVIA entitled ‘Excellence in the UK Research Ecosystem’, which explores the strengths of the UK as a location for clinical research and makes recommendations as to how the UK can stay ahead of the curve in a fast moving, innovative and globally competitive environment. The Northern Prime Site investment by IQVIA means that four out of the 38 IQVIA Prime Sites worldwide are now UK-located, and further cements the IQVIA commitment to the UK’s vibrant life sciences ecosystem.
The initiative is an embodiment of IQVIA’s plans to invest £24m in the North of England regional health economy, as part of the UK’s second Life Sciences Sector Deal in December 2018.
Tim Sheppard, Senior Vice President & GM UKI & Northern Europe, IQVIA said:
“This is a transformational step forward for clinical research in the North of England. We believe that this new collaboration between IQVIA and the NIHR with data enabled researchers across the North of England will be a win/win for local patients and the wider economy.
“Our Prime Sites bring new investment in clinical trials that further cements the UK’s reputation as a primary location for world-leading research. This newest site across Greater Manchester, Leeds and Sheffield ensures that patients will now have even more access to innovative trials, which hold the promise of transforming health outcomes in the future.
“This event is a great opportunity to celebrate our new agreement and the benefit it brings to patients, the NHS and the economy in the region.”
Chief Executive of the National Institute for Health Research, Dr Jonathan Sheffield OBE FRCPath added:
“The National Institute for Health Research (NIHR) Clinical Research Network’ has a mission to see high quality research studies are available for patients across the NHS in England. The Northern Prime site is an expansion of a longstanding collaboration between the NIHR, NHS and IQVIA. It gives an even greater opportunity for patients to contribute to the proving of transforming therapies for their illnesses and reinforces the message that the UK is the best destination for the development of new treatments.”
IQVIA (NYSE: IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialisation, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analysing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviours and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.